Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Win

20 Jul 2005 08:30

Angle PLC20 July 2005 For Immediate Release 20 July 2005 ANGLE plc Wins Contract With The BioBusiness Alliance of Minnesota ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce that its US Consulting and Management division has won acontract with The BioBusiness Alliance of Minnesota, worth $200,000, to conducta comprehensive assessment of the state's biobusiness capabilities. The BioBusiness Alliance of Minnesota is an industry-driven, businessdevelopment organisation of representatives from established and emergingMinnesota companies, universities and government. It is devoted to building thebioscience industry, retaining and creating jobs and economic growth, andpositioning Minnesota as a global leader in biobusiness. The Minnesotabiobusiness industry includes many World-class businesses and institutions suchMedtronic, 3M and the Mayo Clinic. The information from the six month assessment, which will conclude in the fourthquarter of 2005, will benchmark Minnesota against other countries and states.The outcome of the process will identify the State's strengths and developmentneeds, and provide recommendations to target specific areas of biobusiness inwhich Minnesota can compete as a global leader. These recommendations willreflect the convergence of technologies, products, and markets that exist in theState, and identify Minnesota's opportunity areas for growth. ANGLE established a Minnesota office in August 2004 in recognition of thesignificant business potential it believes exists in this State. ANGLE waschosen following a rigorous national and international selection process. ANGLEwas selected for their significant experience both in conducting assessments inthe U.S. and internationally, and for their consulting expertise in thetechnology industry. Dr. Gary P. Evans, CEO of ANGLE's US Operations, said: "We are delighted that ANGLE has been selected to deliver this innovative,industry-driven assessment of Minnesota's biobusiness capabilities. We lookforward to working with the BioBusiness Alliance team to take the first step inthe long-term planning and development of a biobusiness strategy for Minnesota." Andrew Newland, Chief Executive of ANGLE plc, said: "This contract is a great example of ANGLE's continuing expansion within theUnited States. The Minnesota region is a prosperous biobusiness arena and thiscontract will position ANGLE alongside some of the biggest names in the market.We expect that Minnesota will emerge as a further key platform for our Venturesbusiness in the US." - ENDS - For further information ANGLE plcAndrew Newland, Chief Executive Tel: +44(0)1483 295830Lisa Smith, Principal Executive, US Operations Tel: +1 301 524 5654 Buchanan Communications Tel: +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to EditorsFounded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. This includes extensiveexpertise in the commercialization of technology, new company formation,investment and corporate finance, Research Park and incubator development andmanagement, and delivery of economic development programs. ANGLE operates fromoffices in the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Jun 20081:07 pmRNSRule 8.3- Angle Plc
23rd May 200811:50 amRNSRule 8.3- Angle Plc
13th May 200811:57 amRNSRule 8.3- Angle Plc
13th May 200811:57 amRNSRule 8.3- Angle Plc
12th May 20081:20 pmRNSRule 8.3-Angle Plc
9th May 200810:00 amRNSPre-close update
25th Apr 20082:42 pmRNSRule 8.3- Angle Plc
7th Apr 20087:01 amRNSStatement re possible offer
20th Mar 20084:48 pmRNSDirector/PDMR Shareholding
14th Feb 20087:01 amRNSSoftware Development
6th Feb 20087:01 amRNSContract Win
5th Feb 20085:33 pmRNSStatement re. Possible Offer
31st Jan 200811:56 amRNSStatement re Possible Offer
31st Jan 20087:01 amRNSInterim Results
25th Jan 200810:39 amRNSHolding(s) in Company
17th Jan 20087:00 amRNSNotice of Results
13th Nov 20077:01 amRNSPre-close Update
7th Nov 200711:30 amRNSHolding(s) in Company
20th Sep 20073:13 pmRNSResult of AGM
20th Sep 20077:01 amRNSAGM Statement
20th Aug 200710:33 amRNSAIM Rule 26
5th Jul 20077:01 amRNSGeomerics Fundraising
5th Jul 20077:01 amRNSPreliminary Results
27th Jun 20077:01 amRNSContract Win
7th Jun 20077:01 amRNSNotice of Results
1st May 20077:03 amRNSTrading Update
5th Apr 20073:39 pmRNSDirector/PDMR Shareholding
20th Mar 20071:40 pmRNSDirector/PDMR Shareholding
14th Feb 20072:21 pmRNSTrade Sales
2nd Feb 200711:16 amRNSHolding(s) in Company
31st Jan 20077:02 amRNSCommercial Sale
31st Jan 20077:02 amRNSNovocellus Update
31st Jan 20077:02 amRNSSenior Appointment
31st Jan 20077:02 amRNSInterim Results
12th Jan 200712:45 pmRNSHolding(s) in Company
9th Jan 200712:57 pmRNSNotice of Results
21st Dec 20064:12 pmRNSTotal Voting Rights
29th Nov 20062:23 pmBUSSerial Entrepreneur Jothy Rosenberg Joins ANGLE Technology Ventures
27th Nov 20061:49 pmRNSContract Award
8th Sep 20067:01 amRNSNon-Executive Appointment
7th Sep 20062:26 pmRNSAGM Statement
28th Jul 200610:37 amRNSDirector/PDMR Shareholding
27th Jul 20067:02 amRNSPreliminary Results
27th Jul 20067:00 amRNSStrategic Partnership
27th Jul 20067:00 amRNSGeomerics IP Validation
17th May 20067:00 amRNSNew Venture Company
15th May 20064:55 pmRNSHolding(s) in Company
8th May 20068:52 amRNSHolding(s) in Company
4th May 20067:01 amRNSNew Venture - Parsortix Inc
5th Apr 20061:54 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.